Literature DB >> 15678098

Postsynaptic 5-HT1B receptors modulate electroshock-induced generalised seizures in rats.

Tania O Stean1, Alan R Atkins, Christian A Heidbreder, Leann P Quinn, Brenda K Trail, Neil Upton.   

Abstract

1. Although an important regulatory role for serotonin (5-HT) in seizure activation and propagation is well established, relatively little is known of the function of specific 5-HT receptor subtypes on seizure modulation. 2. The aim of the present study was to investigate the role of 5-HT(1A, 1B and 1D) receptors in modulating generalised seizures in the rat maximal electroshock seizure threshold (MEST) test. 3. The mixed 5-HT receptor agonists SKF 99101 (5-20 mg kg(-1) i.p.) and RU 24969 (1-5 mg kg(-1) i.p.), 0.5 h pretest, both produced marked dose-related increases in seizure threshold. These agents share high affinity for 5-HT(1A, 1B and 1D) receptors. 4. Antiseizure effects induced by submaximal doses of these agonists were maintained following p-chlorophenylalanine (150 mg kg(-1) i.p. x 3 days)-induced 5-HT depletion. 5. The anticonvulsant action of both SKF 99101 (15 mg kg(-1) i.p.) and RU 24969 (2.5 mg kg(-1) i.p.) was dose-dependently abolished by the selective 5-HT1B receptor antagonist SB-224289 (0.1-3 mg kg(-1) p.o., 3 h pretest) but was unaffected by the selective 5-HT1A receptor antagonist WAY 100635 (0.01-0.3 mg kg(-1) s.c., 1 h pretest). This indicates that 5-HT1B receptors are primarily involved in mediating the anticonvulsant properties of these agents. 6. In addition, the ability of the 5-HT(1B/1D) receptor antagonist GR 127935 (0.3-3 mg kg(-1) s.c., 60 min pretest) to dose-dependently inhibit SKF 99101-induced elevation of seizure threshold also suggests possible downstream involvement of 5-HT1D receptors in the action of this agonist, although confirmation awaits the identification of a selective 5-HT1D receptor antagonist. 7. Overall, these data demonstrate that stimulation of postsynaptic 5-HT1B receptors inhibits electroshock-induced seizure spread in rats.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15678098      PMCID: PMC1576040          DOI: 10.1038/sj.bjp.0706027

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

1.  Pharmacological analysis of the behavioural and thermoregulatory effects of the putative 5-HT1 receptor agonist, RU 24969, in the rat.

Authors:  M D Tricklebank; D N Middlemiss; J Neill
Journal:  Neuropharmacology       Date:  1986-08       Impact factor: 5.250

2.  Effect of beta-adrenoceptor antagonists and some related drugs on maximal electroshock seizures in mice.

Authors:  N Khanna; A Ray; M Alkondon; P Sen
Journal:  Indian J Exp Biol       Date:  1989-02       Impact factor: 0.818

3.  SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors.

Authors:  G W Price; M J Burton; L J Collin; M Duckworth; L Gaster; M Göthert; B J Jones; C Roberts; J M Watson; D N Middlemiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1997-09       Impact factor: 3.000

4.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves.

Authors:  A DeLean; P J Munson; D Rodbard
Journal:  Am J Physiol       Date:  1978-08

Review 5.  How does pindolol improve antidepressant action?

Authors:  F Artigas; P Celada; M Laruelle; A Adell
Journal:  Trends Pharmacol Sci       Date:  2001-05       Impact factor: 14.819

6.  Serotonergic lesioning differentially affects presynaptic and postsynaptic 5-HT1B receptor mRNA levels in rat brain.

Authors:  J F Neumaier; P Szot; E R Peskind; D M Dorsa; M W Hamblin
Journal:  Brain Res       Date:  1996-05-25       Impact factor: 3.252

7.  Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist.

Authors:  A Fletcher; E A Forster; D J Bill; G Brown; I A Cliffe; J E Hartley; D E Jones; A McLenachan; K J Stanhope; D J Critchley; K J Childs; V C Middlefell; L Lanfumey; R Corradetti; A M Laporte; H Gozlan; M Hamon; C T Dourish
Journal:  Behav Brain Res       Date:  1996       Impact factor: 3.332

8.  Action potential-dependent output of 5-hydroxytryptamine in the anaesthetized rat amygdalopiriform cortex is strongly inhibited by tonic 5-HT1B-receptor stimulation.

Authors:  I Kikvadze; G A Foster
Journal:  Brain Res       Date:  1995-09-18       Impact factor: 3.252

9.  Reduced uptake and release of 5-hydroxytryptamine and taurine in the cerebral cortex of epileptic El mice.

Authors:  M Hiramatsu; K Ogawa; H Kabuto; A Mori
Journal:  Epilepsy Res       Date:  1987-01       Impact factor: 3.045

10.  SB-224289--a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity.

Authors:  J V Selkirk; C Scott; M Ho; M J Burton; J Watson; L M Gaster; L Collin; B J Jones; D N Middlemiss; G W Price
Journal:  Br J Pharmacol       Date:  1998-09       Impact factor: 8.739

View more
  3 in total

Review 1.  The role of different serotonin receptor subtypes in seizure susceptibility.

Authors:  Mohammad Hadi Gharedaghi; Mohammad Seyedabadi; Jean-Eric Ghia; Ahmad Reza Dehpour; Reza Rahimian
Journal:  Exp Brain Res       Date:  2013-11-14       Impact factor: 1.972

2.  Simultaneous blockade of 5-HT1A/B receptors and 5-HT transporters results in acute increases in extracellular 5-HT in both rats and guinea pigs: in vivo characterization of the novel 5-HT1A/B receptor antagonist/5-HT transport inhibitor SB-649915-B.

Authors:  Zoë A Hughes; Kathryn R Starr; Claire M Scott; Michael J Newson; Trevor Sharp; Jeannette M Watson; Jim J Hagan; Lee A Dawson
Journal:  Psychopharmacology (Berl)       Date:  2007-01-30       Impact factor: 4.415

3.  Involvement of nNOS, and α1, α2, β1, and β2 Subunits of Soluble Guanylyl Cyclase Genes Expression in Anticonvulsant Effect of Sumatriptan on Pentylenetetrazole-Induced Seizure in Mice.

Authors:  Faiza Mumtaz; Hamed Shafaroodi; Sadaf Nezamoleslami; Muhammad Zubair; Mohammad Sheibani; Vahid Nikoui; Mahmoud Ghazi-Khansari; Ahmad Reza Dehpour
Journal:  Iran J Pharm Res       Date:  2020       Impact factor: 1.696

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.